Carboplatin

Specifications / Handling

More Information
Product Details
Synonyms	cis-Diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II); NSC201345; NSC241240; JM-8; Paraplatin; Cbdca
Product Type	Chemical
Properties
Formula	C₆H₁₂N₂O₄Pt
MW	371.3
Merck Index	14: 1822
CAS	41575-94-4
RTECS	TP2300000
Purity Chemicals	≥98%
Appearance	White to off-white powder.
Solubility	Soluble in water.
Identity	Determined by ¹H-NMR.
InChi Key	YAYRGNWWLMLWJE-UHFFFAOYSA-L
Smiles	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry. Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Potent platinum-based antineoplastic agent. Analog of cisplatin (Prod. No. AG-CR1-3590) with reduced nephrotoxicity and higher stability.
Antitumor agent.
Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death.
Interferes with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair is impossible.
Apoptosis inducer.
Enhances radiation-induced single-strand DNA breakage.
Chk2 inhibition with carboplatin selectively kills Wwox-deficient cells

Product References

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function: S.J. Harland, et al.; Cancer Res. 44, 1693 (1984)
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer: I.E. Smith, et al.; Cancer Treat Rep. 69, 43 (1985)
Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer: I.E. Smith & B.D. Evans; Cancer Treat Rev. 12 (Suppl. A), 73 (1985)
Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks: L.X. Yang, et al.; Radiation Res. 143, 302 (1995)
Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum (II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited: G. Natarajan, et al.; Biochem. Pharmacol. 58, 1625 (1999)
Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin: O. Heudi, et al.; Biopharm. Drug Dispos. 20, 107 (1999)
What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity: J.P. Thomas, et al.; Mol. Pharmacol. 70, 23 (2006)
p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis: S. Singh, et al.; FEBS Lett. 581, 289 (2007)
Inhibition of transcription by platinum antitumor compounds: R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009)
Application of electric cell-substrate impedance sensing toward personalized anti-cancer therapeutic selection: A.F. Adcock, et al.; J. Analyt. Sci. Tec. 9, 17 (2018)
Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells: M.S. Chesnokov, et al.; Cell Death Dis. 12, 704 (2021)
Interaction of Wwox with Brca1 and associated complex proteins prevents premature resection at double-strand breaks and aberrant homologous recombination: D. Park, et al.; DNA Rep. in press (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049